International Journal of Inflammation / 2013 / Article / Tab 5

Clinical Study

Cost Effectiveness of TNF- Inhibitors in Rheumatoid Arthritis

Table 5

Resulting ICERs in terms of improvement in the SF-6D.

Patient numberCost differences between Treatment A and BDifference in SF-6D between Treatment A and BICER per unit of improvement in the SF-6DICER per 10% improvement in the SF-6D

Patient 1€6,4510.35€18,431€1,843
Patient 2 €5,2180.36€14,494€1,449
Patient 3 €5,4440.22€24,745€2,475
Patient 4€6,4890.19€34,152€3,415
Patient 5€5,3020.18€29,456€2,946
Patient 6€6,5360.31€21,084€2,108
Patient 7€6,4760.18€35,978€3,598
Patient 8€4,8910.19€25,742 €2,574
Patient 9€5,7050.19€30,026 €3,003
Patient 10€6,5080.24€27,117€2,712
Patient 11€5,6490.37€15,268€1,527
Patient 12€6,3250.32€19,766€1,977
Patient 13€1,8020.37€4,870€487
Average€5,6000.27€23,164€2,316

The ICERs per unit improvement and per 10% improvement in the SF-6D following 6 months of TNF-α inhibitor therapy.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.